{
  "id": "5e30f638fbd6abf43b000045",
  "type": "yesno",
  "question": "Does teplizumab hold promise for diabetes prevention?",
  "ideal_answer": "Yes, teplizumab is promising for diabetes prevention.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/23086558",
    "http://www.ncbi.nlm.nih.gov/pubmed/30569273",
    "http://www.ncbi.nlm.nih.gov/pubmed/25941654",
    "http://www.ncbi.nlm.nih.gov/pubmed/31533907",
    "http://www.ncbi.nlm.nih.gov/pubmed/22968521",
    "http://www.ncbi.nlm.nih.gov/pubmed/31523950",
    "http://www.ncbi.nlm.nih.gov/pubmed/20095914",
    "http://www.ncbi.nlm.nih.gov/pubmed/23231526",
    "http://www.ncbi.nlm.nih.gov/pubmed/23835333",
    "http://www.ncbi.nlm.nih.gov/pubmed/24517093",
    "http://www.ncbi.nlm.nih.gov/pubmed/21719095"
  ],
  "snippets": [
    {
      "text": "Anti-CD3 teplizumab and anti-CD3 otelixizumab have been shown to provide C-peptide preservation. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25941654",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Underway are secondary prevention studies with teplizumab and with abatacept.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23231526",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTERPRETATION: Findings of exploratory analyses suggest that future studies of immunotherapeutic intervention with teplizumab might have increased success in prevention of a decline in \u03b2-cell function (measured by C-peptide) and provision of glycaemic control at reduced doses of insulin if they target patients early after diagnosis of diabetes and children.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21719095",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Teplizumab therapy for type 1 diabetes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20095914",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Teplizumab for treatment of type 1 diabetes mellitus.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22968521",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "TAKE HOME MESSAGE\n\nIn Phase I/II randomized control trials, in patients with new onset T1D, teplizumab slowed the rate of loss of beta-cell function over 2 years of follow-up.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20095914",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Teplizumab for treatment of type 1 diabetes (Prot\u00e9g\u00e9 study): 1-year results from a randomised, placebo-controlled trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21719095",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "INTERPRETATION\n\nFindings of exploratory analyses suggest that future studies of immunotherapeutic intervention with teplizumab might have increased success in prevention of a decline in \u03b2-cell function (measured by C-peptide) and provision of glycaemic control at reduced doses of insulin if they target patients early after diagnosis of diabetes and children.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21719095",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Treatment of new onset type 1 diabetes with teplizumab: successes and pitfalls in development.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24517093",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "AREAS COVERED\n\nIn this review, we discuss the recent update on clinical data obtained from trials of teplizumab in type 1 diabetes, the drug's postulated mechanism of action and the identification of responders to therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24517093",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS Teplizumab is an anti-CD3 human monoclonal antibody with promising activity in treatment of patients with T1DM.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22968521",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The results from the TN-10 teplizumab prevention trial show that the diagnosis of type 1 diabetes can be delayed by treatment with a FcR non-binding monoclonal antibody to CD3 in people at high risk for disease",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31533907",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTERPRETATION\nFindings of exploratory analyses suggest that future studies of immunotherapeutic intervention with teplizumab might have increased success in prevention of a decline in \u03b2-cell function (measured by C-peptide) and provision of glycaemic control at reduced doses of insulin if they target patients early after diagnosis of diabetes and children.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21719095",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23835333",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23086558",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The results from the TN-10 teplizumab prevention trial show that the diagnosis of type 1 diabetes can be delayed by treatment with a FcR non-binding monoclonal antibody to CD3 in people at high risk for disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31533907",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Findings of exploratory analyses suggest that future studies of immunotherapeutic intervention with teplizumab might have increased success in prevention of a decline in \u03b2-cell function (measured by C-peptide) and provision of glycaemic control at reduced doses of insulin if they target patients early after diagnosis of diabetes and children.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21719095",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Despite decades of research and clinical trials, no treatment exists yet to prevent or cure T1D. A recent prevention trial using the anti-CD3 antibody teplizumab in individuals at a high risk of developing T1D has provided the first piece of evidence that a safe and transient intervention may be able to delay disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31523950",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In this review, we discuss the recent update on clinical data obtained from trials of teplizumab in type 1 diabetes, the drug's postulated mechanism of action and the identification of responders to therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24517093",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7\u00a0years from diagnosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30569273",
      "beginSection": "title",
      "endSection": "title"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}